Literature DB >> 408269

Rabies virus glycoprotein. II. Biological and serological characterization.

J H Cox, B Dietzschold, L G Schneider.   

Abstract

Purified rabies virus glycoprotein (G) was shown by complement fixation and immunodiffusion tests to be a second distinct antigen of the virus. It it the only structural protein of the virus that induces the formation of virus-neutralizing antibodies and which confers immunity to animals. When the G protein is taken as antigen, the complement fixation test can be used for the assay of virus-neutralizing antibodies. The total protective activity of the virus was recovered in the purified G protein preparation. The protective activity of G protein increased with purification: 9 ng of G protein was required to protect 50% of the mice as compared to 1.63 micrograms of the virus. Selective immunofluorescent membrane staining and immunocytolysis of rabies virus-infected cells were shown to be G protein specific. Due to its purity and potency, the G protein preparation can be considered the ideal human antirabies vaccine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408269      PMCID: PMC421026          DOI: 10.1128/iai.16.3.754-759.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  SYRIAN HAMSTER FIBROBLAST CELL LINE BHK21 AND ITS DERIVATIVES.

Authors:  M STOKER; I MACPHERSON
Journal:  Nature       Date:  1964-09-26       Impact factor: 49.962

2.  EVALUATION OF INDIRECT FLUORESCENT ANTIBODY TECHNIQUE FOR DETECTION OF RABIES ANTIBODY IN HUMAN SERA.

Authors:  J B THOMAS; R K SIKES; A S RICKER
Journal:  J Immunol       Date:  1963-12       Impact factor: 5.422

3.  STUDIES ON THE LOW EGG PASSAGE FLURY STRAIN OF MODIFIED LIVE RABIES VIRUS PRODUCED IN EMBRYONATING CHICKEN EGGS AND TISSUE CULTURE.

Authors:  D J DEAN; W M EVANS; W R THOMPSON
Journal:  Am J Vet Res       Date:  1964-05       Impact factor: 1.156

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Isolation of a hemagglutinating, immunizing, and non-infectious subunit of the rabies virion.

Authors:  L G Schneider; M Horzinek; R Novický
Journal:  Arch Gesamte Virusforsch       Date:  1971

6.  Investigating the rabies virus.

Authors:  K Hummeler; H Koprowski
Journal:  Nature       Date:  1969-02-01       Impact factor: 49.962

7.  [Extraction of a soluble antigen (a glycoprotein) from rabies tissue culture vaccines using Triton X100. Immunization and protection experiments (author's transl)].

Authors:  P Atanasiu; H Tsiang; P Perrin; S Favre; J Sisman
Journal:  Ann Microbiol (Paris)       Date:  1974-12

Review 8.  Structure and molecular biology of rabies virus.

Authors:  L G Schneider; H Diringer
Journal:  Curr Top Microbiol Immunol       Date:  1976       Impact factor: 4.291

9.  Laboratory techniques in rabies: methods of calculation.

Authors:  R J Lorenz; K Bögel
Journal:  Monogr Ser World Health Organ       Date:  1973

10.  Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine.

Authors:  J H Cox; L G Schneider
Journal:  J Clin Microbiol       Date:  1976-02       Impact factor: 5.948

View more
  70 in total

1.  Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection.

Authors:  D L Lodmell; J W Sumner; J J Esposito; W J Bellini; L C Ewalt
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.

Authors:  B Dietzschold; M Gore; D Marchadier; H S Niu; H M Bunschoten; L Otvos; W H Wunner; H C Ertl; A D Osterhaus; H Koprowski
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Antigenicity of rabies virus glycoprotein.

Authors:  A Benmansour; H Leblois; P Coulon; C Tuffereau; Y Gaudin; A Flamand; F Lafay
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  High level expression of a functionally active cholera toxin B: rabies glycoprotein fusion protein in tobacco seeds.

Authors:  Siddharth Tiwari; Devesh K Mishra; Sribash Roy; Ankit Singh; P K Singh; Rakesh Tuli
Journal:  Plant Cell Rep       Date:  2009-10-10       Impact factor: 4.570

5.  Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice.

Authors:  Milosz Faber; Michael Bette; Mirjam A R Preuss; Rojjanaporn Pulmanausahakul; Jennifer Rehnelt; Matthias J Schnell; Bernhard Dietzschold; Eberhard Weihe
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Comparison of representative strains of infectious hematopoietic necrosis virus by serological neutralization and cross-protection assays.

Authors:  H M Engelking; J B Harry; J A Leong
Journal:  Appl Environ Microbiol       Date:  1991-05       Impact factor: 4.792

7.  Polygenic control of antibody production and correlation with vaccine induced resistance to rabies virus in high and low antibody responder mice.

Authors:  M De Franco; S Massa; R C Vassão; M Siqueira; O A Sant'Anna
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  The rabies virus glycoprotein determines the distribution of different rabies virus strains in the brain.

Authors:  Xiuzhen Yan; Puliyur S Mohankumar; Bernhard Dietzschold; Matthies J Schnell; Zhen F Fu
Journal:  J Neurovirol       Date:  2002-08       Impact factor: 2.643

9.  Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.

Authors:  R Pulmanausahakul; M Faber; K Morimoto; S Spitsin; E Weihe; D C Hooper; M J Schnell; B Dietzschold
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask).

Authors:  Benjamin M Davis; Glenn F Rall; Matthias J Schnell
Journal:  Annu Rev Virol       Date:  2015-06-24       Impact factor: 10.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.